![](/img/cover-not-exists.png)
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma
Reardon, David A., Lassman, Andrew B., Schiff, David, Yunus, Shakeeb A., Gerstner, Elizabeth R., Cloughesy, Timothy F., Lee, Eudocia Quant, Gaffey, Sarah C., Barrs, Jennifer, Bruno, Jennifer, MuzikansLanguage:
english
Journal:
Cancer
DOI:
10.1002/cncr.31172
Date:
December, 2017
File:
PDF, 277 KB
english, 2017